Cerepeut Finds Alzheimer's 'Engine' in Cell Powerhouse, Reveals Drug to Stop It

SAN CARLOS, CA – August 06, 2026 – In a discovery that could fundamentally reshape the fight against neurodegenerative disease, scientists at Cerepeut, Inc. have identified what they describe as a “self-sustaining engine” of brain cell death at the heart of Alzheimer’s disease. The breakthrough, published today in the prestigious journal Neuron, pinpoints a previously unknown mechanism within the cell’s own power plants—the mitochondria—that creates a devastating feedback loop, and unveils a new drug candidate designed to shut it down.

The findings move beyond the well-trodden ground of amyloid plaques and tau tangles to reveal a more fundamental, upstream cause of the disease. For decades, researchers have known that a protein called tau forms toxic clumps in the brains of Alzheimer's patients. Cerepeut’s research now shows that tau has a secret, destructive job inside mitochondria, creating a vicious cycle that accelerates neurodegeneration. More importantly, the company’s lead compound, CP-235, has demonstrated in extensive preclinical studies that it can break this cycle.

A Vicious Cycle in the Cell's Powerhouse

The central villain in this newly discovered biological drama is a toxic form of the tau protein known as phosphorylated tau, or pTau. While tau’s role in forming tangles that clog neurons is infamous, the study led by Cerepeut cofounders Bingwei Lu, Ph.D., of Stanford, and Su Guo, Ph.D., of UCSF, reveals it has another, more insidious function.

The research shows for the first time that pTau can directly infiltrate mitochondria and hijack a process called reverse electron transport (RET). In healthy cells, RET is a tightly controlled biological process. However, in diseased or aging brain cells, pTau's interference sends RET into overdrive. This overactivation generates a storm of damaging reactive oxygen species (oxidative stress) and, crucially, signals the cell to produce even more pTau.

This creates the self-perpetuating feedback loop. pTau triggers overactive RET, and overactive RET creates more pTau, which feeds back to make the problem even worse. “Once that loop takes hold, it becomes a self-sustaining engine of neurodegeneration,” said Dr. Lu in the company's announcement. The research team confirmed that this overactive RET signal wasn't just a phenomenon in lab models; they found the same mechanism at work in human brain tissue from Alzheimer's patients, validating it as a critical feature of the human disease.

Breaking the Loop: The Promise of CP-235

Identifying a problem is one thing; solving it is another. Cerepeut’s landmark study also details the effects of its lead drug candidate, CP-235, a first-in-class small molecule specifically designed to inhibit pathological RET. By targeting RET, the compound effectively cuts the power to the neurodegenerative engine.

The results were striking across a range of models. In studies involving fruit flies, genetically engineered mice, and—most significantly—human neurons derived from stem cells, CP-235 broke the pTau-RET cycle. This intervention successfully lowered pTau levels, protected neurons from dying, reduced brain atrophy, and calmed the chronic neuroinflammation associated with the disease. Critically, the compound rescued cognitive deficits in animal models, demonstrating a functional benefit beyond cellular metrics. The drug was also shown to be highly targeted, reducing pathological pTau without affecting overall tau levels, which is vital for normal cell function.

“We now have a therapeutic candidate, and a validated biological target in RET that gets at the root cause of pTau-driven brain disease rather than only mopping up after the damage is done,” said Hua Tu, Ph.D., President and CEO of Cerepeut. He also highlighted the compound’s excellent safety profile in these models, adding, “CP-235 was well tolerated across every model we tested, so we believe RET is not just a promising target, it's a druggable one.”

Shifting the Paradigm in Neurodegeneration

The implications of this discovery extend far beyond the laboratory. For years, the Alzheimer's therapeutic landscape has been dominated by drugs targeting amyloid plaques, with recent approvals like Leqembi showing modest, albeit important, benefits. However, the field has been searching for next-generation therapies that can offer more profound, disease-modifying effects. Cerepeut’s approach represents a significant paradigm shift by targeting a different and more fundamental aspect of the disease pathology.

“Breaking the loop, rather than only clearing tau after the fact, is a powerful way to change the course of disease,” Dr. Lu explained. This strategy aims to prevent the damage from starting, a stark contrast to therapies that address downstream consequences.

Furthermore, the pTau-RET mechanism is not believed to be exclusive to Alzheimer's. It may be a common pathway across a range of devastating “tauopathies”—diseases defined by toxic tau aggregation. This includes progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), and corticobasal degeneration (CBD), all of which currently lack effective treatments. By targeting this shared root cause, CP-235 could potentially become a broad-spectrum therapy for multiple neurodegenerative disorders, dramatically increasing its potential impact.

From Lab Bench to Bedside: Cerepeut's Path Forward

For a small biotech company like Cerepeut, publishing such a foundational study in a top-tier journal is a massive validation of its scientific strategy. The company’s mission—to restore mitochondrial resilience—is built on the world-class research of its founders from Stanford and UCSF, whose prior work laid the scientific groundwork for this breakthrough. By not only identifying a novel disease mechanism but also presenting a purpose-built molecule to correct it, Cerepeut has established significant credibility.

The discovery does more than just introduce a new drug; it validates RET as a new “druggable target” in the central nervous system. This opens up a new frontier for therapeutic development, one that could attract significant investment and partnership interest from larger pharmaceutical players.

Of course, the path from preclinical success to an approved medicine is long and fraught with challenges, particularly in neuroscience. The high failure rate of drugs in human clinical trials is a sobering reality. However, the robustness of Cerepeut's data across multiple relevant models, including human iPSC-derived neurons, provides a stronger foundation than many earlier-stage programs. Cerepeut has announced it is advancing its lead program toward clinical development, where the true potential of CP-235 to alter the course of human neurodegenerative disease will finally be tested.